Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$629K Hold
4,863
– – 0.38% 46
2026
Q1
$589K Hold
4,863
– – 0.41% 40
2025
Q4
$515K Buy
4,863
+869
+22% +$81.6K 0.34% 48
2025
Q3
$338K Hold
3,994
– – 0.23% 62
2025
Q2
$312K Hold
3,994
– – 0.23% 62
2025
Q1
$362K Sell
3,994
-200
-5% -$18.7K 0.33% 48
2024
Q4
$421K Hold
4,194
– – 0.36% 44
2024
Q3
$480K Hold
4,194
– – 0.42% 43
2024
Q2
$526K Buy
+4,194
New +$540K 0.47% 35

Other funds holding MRK

Fairscale Capital's MRK Position: Q2 2026 in Review

Fairscale Capital held its Merck (MRK) position steady in Q2 2026 at 4,863 shares worth $629K. The position accounts for 0.38% of the portfolio, ranked #46.

Fairscale Capital first reported a position in MRK in Q2 2024 and has held it in 9 quarters since. 3,852 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Fairscale Capital held 4,863 shares of Merck worth $629K as of Q2 2026.
  • Fairscale Capital left its Merck share count unchanged in Q2 2026.
  • Merck made up 0.38% of Fairscale Capital's portfolio in Q2 2026, its #46 holding.
  • Fairscale Capital first reported a position in Merck in Q2 2024 and has held it in 9 quarters since.
  • 3,852 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Fairscale Capital's 13F filing for Q2 2026, filed 7 Aug 2026.